

16.19.20.45 PRESCRIPTION ~~FILL~~ AND REFILL REQUIREMENTS:

A. Prescriptions for any controlled substance shall not be filled more than six months after the date of issue.

(1) Controlled substance prescriptions dispensed directly to a patient shall not be refilled before seventy-five percent of the prescription days' supply has passed, unless the practitioner authorizes the early refill, which must be documented by the pharmacist.

(2) Controlled substance prescriptions delivered to a patient indirectly (as mail order) to a patient shall not be refilled before sixty-six percent of a 90 day supply has passed or fifty percent of a 30 day supply has passed, unless the practitioner authorizes the early refill, which must be documented by the pharmacist.

B. Prescriptions for Schedule III, IV, or V controlled substances shall not be filled or refilled more than six months after the date of issue or be ~~filled~~ refilled more than five times unless renewed by the practitioner and a new prescription is placed in the pharmacy files.

[16.19.20.45 NMAC - Rp 16 NMAC 19.20.20(4), 07-15-02; A, 08-31-12; A, 10-19-16]

16.19.20.46 PRESCRIPTION - PARTIALLY ~~REFILLED~~:

A. A prescription for a controlled substance in Schedule II may be partially filled if the total quantity dispensed in all partial fillings does not exceed the total quantity prescribed. Remaining portions shall be filled not later than 30 days after the date on which the prescription is written.

B. A Schedule II prescription may be partially filled if the amount is recorded on the prescription. The remaining portion may be filled within 72 hours of the partial filling for prescriptions initially filled later than 30 days after the date on which the prescription is written. Pharmacist must notify the prescribing physician if remaining portion cannot be filled within a 72 hour period.

BC. Partial filling of a prescription for Schedule III or IV shall be recorded in the same manner as a refill, providing the total quantity of partial filling does not exceed the total quantity prescribed and no dispensing occurs after six months from date of prescription.

ED. A prescription for a Schedule II controlled substance written for a patient in a long term care facility (LTCF) or for a patient with a medical diagnosis documenting a terminal illness may be filled in partial quantities, to include individual dosage units.

(1) If there is any question whether a patient may be classified as having a terminal illness, the pharmacist shall contact the practitioner prior to partially filling the prescription. Both the pharmacist and the prescribing practitioner have a corresponding responsibility to assure that the controlled substance is for a terminally ill patient. The pharmacist shall record on the prescription whether the patient is "terminally ill" or an "LTCF patient".

(2) A prescription that is partially filled and does not contain the notation "terminally ill" or "LTCF patient" shall be deemed to have been filled in violation of this regulation. For each partial filling, the dispensing pharmacist shall record on the back of the prescription (or on appropriate record, uniformly maintained, and readily retrievable) the date of the partial filling, quantity dispensed, remaining quantity authorized to be dispensed and the identification of the dispensing pharmacist.

(3) The total quantity of Schedule II controlled substances dispensed in all partial fillings shall not exceed the total quantity prescribed. Schedule II prescriptions, for patients in a LTCF or patients with a medical diagnosis documenting a terminal illness, shall be valid for a period not to exceed 60 days from the issue date unless sooner terminated by the discontinuance of medication.

[16.19.20.46 NMAC - Rp 16 NMAC 19.20.20(5), 07-15-02; A, 03-29-17]

16.19.20.65 SCHEDULE I:

A. Section 30-31-6 NMSA 1978, Schedule I shall consist of the following drugs and other substances, by whatever name, common or usual name, chemical name or brand name designated, listed in this section; OPIATES NARCOTIC DRUGS, unless specifically exempt or unless listed in another schedule, any of the following opiates narcotic drugs, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.

(1) Acetylmethadol

- (2) Allylprodine
- (3) Alphacetylmethadol
- (4) Alphameprodine
- (5) Alphamethadol
- (6) Alpha-methyl fentanyl
- (7) Benzethidine
- (8) Betacetylmethadol
- (9) Betameprodine
- (10) Betamethadol
- (11) Betaprodine
- (12) Clonitazene
- (13) Desmethyltramadol
- (14) Dextromoramide
- (15) Diampromide
- (16) Diethylthiambutene
- (17) Dimethylthiambutene
- (18) Difenoxin
- (19) Dimenoxadol
- (20) Dimepheptanol
- (21) Dimethylthiambutene
- (22) Dioxaphetyl Butyrate
- (23) Dipipanone
- (24) Ethylmethylthiambutene
- (25) Etonitazene
- (26) Etoxidine
- (27) Furethidine
- (28) Hydroxypethidine
- (29) Ketobemidone
- (30) Levomoramide
- (31) Levophenacymorphan
- (32) Morpheridine
- (33) Noracymethadol
- (34) Norlevorphanol
- (35) Normethadone
- (36) Norpipanone
- (37) Phenadoxone
- (38) Phenampromide
- (39) Phenomorphan
- (40) Phenoperidine
- (41) Piritramide
- (42) Proheptazine
- (43) Properidine
- (44) Propiram
- (45) Racemoramide
- (46) Tilidine
- (47) Trimeperidine
- ~~(24)~~(48) Beta-Hydroxy-3-Methylfentanyl
- ~~(25)~~(49) 3-Methylthiofentanyl
- ~~(26)~~(50) Acetyl-Alpha-Methyl fentanyl
- ~~(27)~~(51) Alpha-Methylthiofentanyl
- ~~(28)~~(52) Beta-hydroxfentanyl
- ~~(29)~~(53) Para-Fluoro fentanyl
- ~~(30)~~(54) Thiofentanyl
- ~~(32)~~(55) Acetyl fentanyl
- ~~(33)~~(56) Butyryl fentanyl
- ~~(34)~~(57) Betahydroxythiofentanyl

~~(35)~~(58) Furanyl fentanyl
~~(36)~~(59) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)
~~(37)~~(60) U47700 (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide)
~~(38)~~(61) MT-45 (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)
~~(39)~~(62) W-15 (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide)
~~(40)~~(63) W-18 (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)
~~(41)~~(64) U-50488 (2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide)
~~(42)~~(65) U50488H ((-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide)

~~(66)~~ Fentanyl mimetic substances that are any substances derived from fentanyl by any substitution in the phenethyl group, any substitution in the piperidine ring, any substitution in the aniline ring, any replacement of the phenyl portion of the phenethyl group, any replacement of the N-propionyl group or any combination of the above.

~~(4)~~(67) 3-methylfentanyl(N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidyl)-N-phenylpropanamide, its optical and geometric isomers, salts and salts of isomers;

~~(3)~~(68) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and salts of isomers;

~~(69)~~ Acrylfentanyl
~~(70)~~ 4F-butyrfentanyl
~~(71)~~ 4-methoxybutyrfentanyl
~~(72)~~ Fluorobutyrfentanyl
~~(73)~~ Fluorofentanyl
~~(74)~~ Para Fluoro Isobutyryl Fentanyl (FIBF)
~~(75)~~ Cyclopropyl fentanyl
~~(76)~~ Thiofuranyl fentanyl (Thiophene fentanyl)
~~(77)~~ U-48800
~~(78)~~ U-49900

B. OPIUM DERIVATIVES: Unless specifically exempt or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.

- (1) Acetorphine
- (2) Acetyl dihydrocodeine
- (3) Benzyl morphine
- (4) Codeine methylbromide
- (5) Codeine-N-Oxide
- (6) Cyprenorphine
- (7) Desomorphine
- (8) Dehydro morphine
- (9) Etorphine
- (10) Heroin
- (11) Hydromorphenol
- (12) Methyldesorphine
- (13) Methyldihydromorphine
- (14) Morphine methylbromide
- (15) Morphine methylsulfonate
- (16) Morphine-N-Oxide
- (17) Myorphine
- (18) Nicocodeine
- (19) Nicomorphine
- (20) Normorphine
- (21) Pholcodine
- (22) Thebacon
- (23) Drotebanol
- ~~(24)~~ Beta Hydroxy 3 Methylfentanyl

- ~~(25) 3-Methylthiofentanyl~~
- ~~(26) Acetyl-Alpha-Methyl-fentanyl~~
- ~~(27) Alpha-Methylthiofentanyl~~
- ~~(28) Beta-hydroxfentanyl~~
- ~~(29) Para-Fluoro-fentanyl~~
- ~~(30) Thiofentanyl~~
- ~~(31) 6-acetylmorphine (6AM)~~
- ~~(32) Acetyl-fentanyl~~
- ~~(33) Butyryl-fentanyl~~
- ~~(34) Betahydroxythiofentanyl~~
- ~~(35) Furanyl-fentanyl~~
- ~~(36) AH 7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)~~
- ~~(37) U47700 (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide)~~
- ~~(38) MT-45 (1-(4-nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)~~
- ~~(39) W-15 (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]benzenesulfonamide)~~
- ~~(40) W-18 (1-(4-nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)~~
- ~~(41) U-50488 (2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide)~~
- ~~(42) U50488H ((-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide)~~

(24) 6-acetylmorphine (6AM)

E.C. STIMULANTS: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.

- (1) fenethylamine;
- (2) N-ethylamphetamine;
- (3) cis-4-methylaminorex;
- (4) N, N-dimethylamphetamine;
- (5) N-benzylpiperazine (BZP, 1-benzylpiperazine);
- (6) 2,3-dichlorophenylpiperazine (DCPP);
- (7) dibenzylpiperazine (DBZP);
- (8) methylbenzylpiperazine (MBZP);
- (9) meta-chlorophenylpiperazine (mCPP);
- (10) methylenedioxybenzylpiperazine (MDBZP);
- (11) para-methoxyphenylpiperazine (meOPP);
- (12) para-chlorophenylpiperazine (pCPP);
- (13) para-fluorophenylpiperazine (pFPP);
- (14) 2-diphenylmethylpiperidine, (2-DPMP, desoxypipradrol);
- (15) diphenyl-2-pyrrolidinemethanol (D2PM, diphenylprolinol);
- (16) methylnaphthidate (HDMP-28);
- (17) 3 α -carbomethoxy-4 β -(4-chlorophenyl)-N-methylpiperidine (Nocaine, (+)-CPCA);
- (18) butyltolylquinuclidine (2-Butyl-3-(p-tolyl)quinuclidine, BTQ);

D. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

- (1) mecloqualone;
- (2) methaqualone;
- (3) benzodiazepines;
 - (a) bromazepam;
 - (b) camazepam;
 - (c) cloxazolam;
 - (d) delorazepam;

- (e) ethylloflazepate;
 - (f) fludiazepam;
 - (g) flunitrazepam;
 - (h) haloxazolam;
 - (i) ketazolam;
 - (j) loprazolam;
 - (k) lormetazepam;
 - (l) medazepam;
 - (m) nimetazepam;
 - (n) nitrazepam;
 - (o) nordiazepam;
 - (p) oxazolam;
 - (q) pinazepam;
 - (r) tetrazepam;
 - (s) flubromazepan
 - (t) diclazepam
- to GHB;
- (4) gamma hydroxybutyric acid and any chemical compound that is metabolically converted
- GHB;
- (5) gamma butyrolactone and any chemical compound that is metabolically converted to
 - (6) 1-4 butane diol and any chemical compound that is metabolically converted to GHB;
 - (7) γ -hydroxyvaleric acid (GHV, 4-methyl-GHB);
 - (8) γ -valerolactone (GVL);
 - (9) methylmethaqualone (MMQ);
 - (10) mebroqualone (MBQ);

C.E. HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term “isomers” includes the optical position, optical, positional and geometric isomers).

- (1) 3,4 -methylenedioxy amphetamine;
 - (2) 5 - methoxy - 3,4-methylenedioxy amphetamine;
 - (3) 3,4,5 -trimethoxy amphetamine;
 - (4) Bufotenine;
 - (5) Diethyltryptamine; DET;
 - (6) Dimethyltryptamine; DMT;
 - (7) 4-methyl-2,5-dimethoxy-amphetamine; DOM or STP;
 - (8) Lysergic acid amide;
 - (9) Lysergic acid diethylamide;
 - (10) Marijuana;
 - (11) Mescaline;
 - (12) Peyote;
 - (13) N-ethyl-3-piperidyl benzilate;
 - (14) N-methyl-3-piperidyl benzilate;
 - (15) Psilocybin;
 - (16) Psilocyn;
 - (17) Tetrahydrocannabinols;
 - (18) Parahexyl (synthetic analog of delta-9-tetrahydrocannabinol (THC) an active ingredient
- of cannabis);
- (19) Hashish;
 - (20) 2, 5 -dimethoxyamphetamine; 2, 5-DMA;
 - (21) 4-bromo-2, 5-dimethoxy-amphetamine; 2, 5-DMA;
 - (22) 4-methoxyamphetamine; PMA;
 - (23) Ethylamine N-ethyl-1-phenylcyclohexylamine (PCE);
 - (24) Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine (PCPy), (PHP) analog of the drug

phencyclidine;

- (25) Thiophene (analog of phencyclidine) TCP or TPCP;
- (26) Alpha-ethyltryptamine;
- (27) 2, 5-dimethoxy-4-ethylamphet-amine;
- (28) Ibogaine;
- (29) 2,5 dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);
- (30) Alpha-methyltryptamine (AMT);
- (31) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- (32) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
- (33) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
- (34) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
- (35) Synthetic cannabinoids: Unless specifically exempted or unless listed in another

schedule, any material, compound, mixture ~~of or~~ preparation which contains any quantity of the following synthetic cannabinoids ~~which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity:~~

- (a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol);
- (b) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol);
- (c) JWH-081 (1-pentyl-3-[1-(4-methoxynaphthoyl)]indole);
- (d) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole);
- (e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H

dibenzo[b,d]pyran;

- (f) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole);
- (g) JWH 210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
- (h) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole);
- (i) AM-1221 (1-(N-methylpiperidin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-

nitroindole;

- (j) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
- (k) RCS-4 or SR-19 (1-pentyl-3-[(4-methoxy)-benzoyl]indole);
- (l) RCS-8 or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole);
- (m) JWH-210 (1-pentyl-3-(4-ethylnaphthoyl)indole);
- (n) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-

ylethyl)indol-3-yl]methanone;

- (o) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin-6-yl)-1-naphthalenylmethanone);

(p) any of the following synthetic cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation;

(i) naphthoylindoles: any compound containing a 3-(1-naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201;

(ii) naphthylmethylindoles: any compound containing a 1Hindol- 3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199;

(iii) naphthoylpyrroles: any compound containing a 3-(1-naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-307;

(iv) naphthylmethylindenes: any compound containing a

naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-176;

(v) phenylacetylindoles: any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8;

(vi) cyclohexylphenols: any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5- position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol (CP 47,497 C8 homologue), CP 47,497 and CP 55,490;

(vii) benzoylindoles: any compound containing a 3-(benzoyl) [5] OTS-3833.4 indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny) methyl, or 2-(4- morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241;

(q) UR-144 1-(pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-

tetramethylcyclopropyl)methanone;

(s) AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide;
(t) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22, QUPIC);
(u) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB22; 5F-PB22);

(v) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA);

(w) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamine (ADB-PINACA);

(x) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA);

(y) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA);

(z) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201);
(aa) FDU-PB-22 IUPAC: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3 carboxylate;
(bb) 5-fluoro ABICA IUPAC: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;

(cc) FUB-144 IUPAC: [1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (AKA FUB-UR-144);

(dd) MN-18 IUPAC: N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide;
(ee) FUB-PB-22 IUPAC: Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-

carboxylate;

(ff) ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

(gg) AMB-FUBINACA, (FUB-AMB), (methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);

(hh) 5-fluoro-AMB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester);

(ii) 5-fluoro-ADB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine, methyl ester);

(jj) bk-DMBDB / dibutylone

(kk) MMB-FUBINACA, methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-

valinate

(ll) MDMB-CHMICA, methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate

(mm) NM2201, Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate

(nn) Fluoro AKB48

(oo) Fluoro ADB

(pp) Fluoro AMB

(qq) MAB-CHMINACA

(rr) SDB-006

(ss) Cumyl-PINACA/Cumyl-PICA

(tt) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of a substance which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity.

(36) Substances determined by the board to have the pharmacological effect of the substance, the risk to the public health by abuse of the substance and the potential of the substance to produce psychic or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA 1978. Substances include but are not limited to:

(a) salvia divinorum;

(b) salvinorin A (methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate);

(37) 4-methyl-ethylcathinone (4-MEC);

(38) 4-ethyl-methcathinone (4-EMC);

(39) 2-ethylamino-1-phenyl-propan-1-one (ethcathinone);

(40) 3',4'-methylenedioxyethylcathinone (ethylone);

(41) beta-keto-N-methyl-3,4-benzodioxolybutanamine (bk-MBDB, butylone);

(42) naphthylpyrovalerone (NRG-1, naphyrone);

(43) N,N-dimethylcathinone (metamfepramone);

(44) alpha-pyrrolidinopropiophenone (alpha-PPP);

(45) alpha-pyrrolidinobutiophenone (α -PBP);

(46) 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP);

(47) 4'-methyl- α -pyrrolidinopropiophenone (MPPPP);

(48) 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP);

(49) 3',4'-methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP);

(50) 4'-methyl- α -pyrrolidinobutiophenone (MPBP);

(51) alpha-pyrrolidinovalerophenone (alpha-PVP);

(52) 5,6-methylenedioxy-2-aminoindane (MDAI);

(53) alpha-methylamino-butyrophenone (buphedrone);

(54) beta-keto-ethylbenzodioxolylbutanamine (eutylone);

(55) beta-keto-ethylbenzodioxolylpentanamine;

(56) beta-keto-methylbenzodioxolylpentanamine (pentylone);

(57) 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus);

(58) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA);

(59) 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT;

(60) 4-methylmethcathinone (Mephedrone);

(61) 3,4-methylenedioxypropylvalerone (MDPV);

(62) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

(63) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

(64) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

(65) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T4);

(66) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

(67) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

- (68) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
- (69) 3,4-Methylenedioxy-N-methylcathinone(Methylone);
- (70) Aminorex (2-amino-5-phenyl-2-oxazoline);
- (71) Pentedrone;
- (72) 4-fluoro-N-methylcathinone (4-FMC; flephedrone);
- (73) 3-fluoro-N-methylcathinone (3-FMC);
- (74) 3-methylmethcathinone (3-MMC);
- (75) 3,4-Dimethylmethcathinone (3,4 DMMC);
- (76) 3-Methyl-N-ethylcathinone (3-MEC);
- (77) 2-methylamino-1-(4-methylphenyl)butan-1-one (4-methylbuphedrone; 4-MeBP);
- (78) 4-methylthioamphetamine (4 MTA);
- (79) 5-methyl-3,4-methylenedioxyamphetamine (5-Me MDA);
- (80) 6-benzofuran (6-APB);
- (81) 4-methoxyamphetamine (PMA);
- (82) 2,5-dimethoxy-4-bromophenethylamine (2C-B);
- (83) 2,5-dimethoxy-4-chlorophenethylamine (2C-C);
- (84) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
- (85) 2,5-dimethoxy-4-ethylphenethylamine, (2C-E, aquarust, cindy);
- (86) 3,4-dimethyl-2,5-dimethoxyphenethylamine (2C-G);
- (87) 2,5-dimethoxy-4-iodophenethylamine (2C-I);
- (88) 2-[2,5-dimethoxy-4-(2-fluoroethylthio)phenyl]ethanamine (2C-T21);
- (89) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY);
- (90) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, (Bromo-DragonFLY, 3C-Bromo-Dragonfly, DOB-Dragonfly);
- (91) 2,5-Dimethoxy-4-bromoamphetamine (DOB);
- (92) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
- (93) 2,5-Dimethoxy-4-methylamphetamine (DOM);
- (94) 2,4,5-trimethoxyamphetamine (TMA2);
- (95) 2,4,6-trimethoxyamphetamine (TMA6);
- (96) 6,7-methylenedioxy-2-aminotetralin (MDAT);
- (97) 4-acetoxy-N,N-diisopropyltryptamine (4-acetoxy DiPT, ipracetin);
- (98) O-Acetylpsilocin (4-acetoxy DMT, psilacetin);
- (99) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO MET, metocin);
- (100) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO MiPT, hats);
- (101) 5-methoxy- α -methyltryptamine, (5-MeO-aMT, Alpha-O);
- (102) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine (5-MeO-MiPT);
- (103) N,N-diisopropyltryptamine (DiPT);
- (104) dipropyltryptamine (DPT);
- (105) N,N-diallyl-5-methoxytryptamine (5-MeO-DALT);
- (106) 3-methoxyphencyclidine (3-MeO PCP);
- (107) 4-methoxyphencyclidine (4-MeO PCP);
- (108) dizocilpine (MK-801);
- (109) tetrachloroethylene (PCE, perchloroethylene, perchloroethene, Perc);
- (110) 3-MeO-2-Oxo-PCE (methoxetamine);
- (111) phencyclamine, N-(1-phenylcyclohexyl)propanamine (PCPr);
- (112) 1-(1-(2-thienyl)cyclohexyl)piperidine (Tenocyclidine);
- (113) 3-methoxyeticyclidine, N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO PCE);
- (114) 6-ethyl-6-nor-lysergic acid diethylamide (ETH-LAD);
- (115) 6-allyl-6-nor-LSD (AL-LAD);
- (116) 10-didehydroergoline-8-carboxamide (PRO-LAD);
- ~~(117)~~ 3, 4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers;
- ~~(118)~~ cathinone;
- ~~(119)~~ methcathinone.
-
- (120) diethylone

F. Any material, compound, mixture ~~o~~for preparation which contains any quantity of the following substances.

~~(1) 3-methylfentanyl(N-3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide, its optical and geometric isomers, salts and salts of isomers;~~

~~(2) 3,4-methylenedioxyamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers;~~

~~(3) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and salts of isomers;~~

~~(4)~~(1) 1-(2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP), its optical isomers, salts and salts of isomers;

~~(5) cathinone;~~

~~(6) methcathinone.~~

~~(2) Tianeptene~~

[16.19.20.65 NMAC - Rp 16 NMAC 19.20.28, 07-15-02; A, 06-30-05; A, 01-15-08; A, 05-14-10; A, 11-27-11; A, 06-15-12; A, 08-31-12; A, 12-19-13; A, 06-28-14; A, 12-13-15; A, 10-19-16; A, 03-29-17]

16.19.20.66 SCHEDULE II:

~~B.A.~~ **OPIATES: NARCOTIC DRUGS:** Unless specifically excepted or unless in another schedule any of the following ~~opiates-narcotic drugs~~, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation except ~~dextrose dextro~~ and levopropoxyphene.

- (1) Alphaprodine
- (2) Anileridine
- (3) Bezitramide
- (4) Diphenoxylate
- (5) Dihydrocodeine
- (6) Dextropropoxyphene (bulk) non-dosage form
- (7) Fentanyl
- (8) Isomethadone
- (9) Levomethorphan
- (10) Levorphanol
- (11) Metazocine
- (12) Methadone
- (13) Methadone-Intermediate
- (14) Monamide-Intermediate
- (15) Pethidine
- (16) Pethidine-Intermediate A
- (17) Pethidine-Intermediate B
- (18) Pethidine-Intermediate C
- (19) Phenazocine
- (20) Piminodine
- (21) Racemethorphan
- (22) Racemorphan
- (23) Sufentanil
- (24) Carfentanil
- (25) Levo-alphaacetylmethadol (LAAM)
- (26) Tapentadol

~~A.B.~~ Shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Substance, vegetable origin or chemical synthesis. Unless specifically exempt or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis.

(1) Opium and opiate, and any salts, compound, derivative, or preparation of opium or opiate excluding naloxone, dextroprhan, nalbuphine, naltrexone and apomorphine but including the following:

- (a) raw opium
- (b) opium extracts
- (c) opium fluid extracts
- (d) powdered opium
- (e) granulated opium
- (f) tincture of opium
- (g) codeine
- (h) ethylmorphine
- (i) etorphine hydrochloride
- (j) hydrocodone
- (k) hydromorphone
- (l) metopon
- (m) morphine
- (n) oxycodone
- (o) oxymorphone
- (p) thebaine
- (q) alfentanil
- (r) oripavine

(2) Any salt, compound derivative, or preparation thereof, which is chemically equivalent or identical with any of the substances referred to in Paragraph (1) of Subsection A of 16.19.20.66 NMAC, except that these substances shall not include the isoquinoline alkaloids of opium.

(3) Opium poppy and poppy straw.

(4) Coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include de-cocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.

C. STIMULANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system. (See 16.19.21 NMAC- Drug Precursors)

- (1) Amphetamine, its salts, optical isomers and salts of its optical isomers.
- (2) Methamphetamine, its salts, isomers and salts of isomers.
- (3) Phenmetrazine and its salts.
- (4) Methylphenidate
- (5) Lisdexamfetamine

D. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule any material, compound mixture or preparation which contains any quantity of the substance having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers is possible within the specific chemical designation.

- (1) Amobarbital
- (2) Secobarbital
- (3) Pentobarbital
- (4) Phencyclidine
- (5) Glutethimide
- (6) 1-phenylcyclohexylamine
- (7) 1-piperidinocyclohexanecarbonitrile

E. HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purpose of this paragraph only, the term "isomers" includes the optical position, optical, positional and geometric isomers):

- (1) Nabilone

(2) Phenylacetone (P2P, benzyl methyl ketone; methyl benzyl ketone)

F. MISCELLANEOUS:

- (1) Dihydroetorphine
- (2) Bulk dextropropoxyphene
- (3) Remifentanyl

[16.19.20.66 NMAC - Rp 16 NMAC 19.20.28(1), 07-15-02; A, 06-30-05; A, 01-15-08; A, 05-14-10; A, 06-28-14; A, 12-13-15]

16.19.20.67 SCHEDULE III: Shall consist of drugs and other substances, by whatever official name, common or usual name designated listed in this section.

E.A. NARCOTIC DRUGS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation containing limited quantities of the following narcotic drugs, or any salts thereof.

- (1) Not more than one and eight-tenths grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
- (2) Not more than one and eight-tenths grams of codeine per 100 milliliters or not more than 90 milligrams per dosage units, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.
- (3) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
- (4) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
- (5) Not more than one and eight-tenths grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
- (6) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
- (7) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
- (8) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

A.B. STIMULANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system.

- (1) Those compounds, mixtures or preparations in dosage unit form containing any stimulant, amphetamine, phenmetrazine or methamphetamine previously exempt, for which the exemption was revoked by FDA Regulation Title 21, Part 308.13, and any other drug of the quantitative composition shown in that regulation for those drugs or which is the same except that it contains a lesser quantity of controlled substances.
- (2) Benzphetamine.
- (3) Phendimetrazine.
- (4) Chlorphentermine.
- (5) Clortermine.

B.C. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system.

- (1) Any compound, mixture or preparation containing:
 - (a) amobarbital;
 - (b) secobarbital;
 - (c) pentobarbital;
 - (d) butalbital; or any salt thereof and one or more active medicinal ingredients which are not listed in any schedule.
- (2) Any suppository dosage form containing:
 - (a) amobarbital;
 - (b) secobarbital;

(c) pentobarbital; or any salt of any of these drugs approved by the FDA for marketing only as a suppository.

(3) Any substance which contains any quantity of a derivative of barbituric acid or any salt of a derivative of barbituric acid.

- (4) Chlorhexadol
- (5) Lysergic Acid
- (6) Lysergic Acid Amide
- (7) Methypylon
- (8) Sulfondiethylmethane
- (9) Sulfonethylmethane
- (10) Sulfonmethane
- (11) Tiletamine/zolazepam (Telazol)
- (12) Ketamine Hydrochloride
- (13) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers,

and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug and Cosmetic Act.

(14) Embutramide

(15) Dronabinol (synthetic) in sesame oil and encapsulated in soft gelatin capsules in a drug product approved by the U.S. food and drug administration.

(16) Perampanel

~~C. Nalorphine (a narcotic drug).~~

~~D. Buprenorphine.~~

D. MISCELLANEOUS

- (1) Nalorphine
- (2) Buprenorphine
- (3) Clenbuterol

F.E. ANABOLIC STEROIDS: The term “anabolic steroid” means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth. Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances listed in this section:

- (1) boldenone
- (2) chloro testosterone
- (3) clostebol
- (4) dehydrochlormethyltestosterone
- (5) dihydrotestosterone
- (6) drostanolone
- (7) ethylestrenol
- (8) fluoxymesterone
- (9) formebolone
- (10) mestanolone
- (11) mesterolone
- (12) methandienone
- (13) methandranone
- (14) methandriol
- (15) methandrosthenolone
- (16) methenolone
- (17) methyltrienolone
- (18) methyltestosterone
- (19) mibolerone
- (20) nandrolone
- (21) norbolethone
- (22) norethandrolone

- (23) oxandrolone
- (24) oxymesterone
- (25) oxymetholone
- (26) stanolone
- (27) stanozolol
- (28) testolactone
- (29) testosterone
- (30) trenbolone; and
- (31) any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if

that salt, ester, or isomer promotes muscle growth.

G.F. Exempt anabolic steroids: Compounds, mixtures, or preparations that contain an anabolic steroid that have been exempted by the board from Subsection E of 16.19.20.67 NMAC, Schedule III to the same extent that the substance has been exempted from the application of the Federal Controlled Substance Act, if the substance is listed as an exempt anabolic steroid product under 21 C.F.R. Section 1308.34 and its subsequent amendments. [16.19.20.67 NMAC - Rp 16 NMAC 19.20.28(2), 07-15-02; A, 02-15-03; A, 06-30-05; A, 01-31-07; A, 01-15-08; A, 05-14-10; A, 06-28-14]

16.19.20.68 SCHEDULE IV: Shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section:

F.A. NARCOTIC DRUG: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof: Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

D.B. STIMULANTS: Unless specifically exempt or unless listed in another schedule any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether ~~optical position~~ optical, positional or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

- (1) Diethylpropion
- (2) Phentermine
- (3) Pemoline (including organometallic complexes and chelates thereon)
- (4) Pipradrol
- (5) SPA ((-)-1-dimethyl amino-1,2-diphenylmethane)
- (6) Mazindol
- (7) Cathine
- (8) Fencamfamin
- (9) Fenproporex
- (10) Mefenorex
- (11) Modafinil
- (12) Sibutramine

A.C. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

- (1) Alfaxalone
- (2) Alprazolam
- (3) Barbitol
- (4) Chloral Betaine
- (5) Chloral Hydrate
- (6) Chlordiazepoxide
- (7) Clobazam
- (8) Clonazepam

- (9) Clorazepate
- (10) Clotiazepam
- (11) Diazepam
- (12) Estazolam
- (13) Ethchlorvynol
- (14) Ethinamate
- (15) Flurazepam
- (16) Fospropofol
- (17) Halazepam
- (18) Lorazepam
- (19) Mebutamate
- (20) Meprobamate
- (21) Methohexital
- (22) Methylphenobarbital
- (23) Midazolam
- (24) Oxazepam
- (25) Paraldehyde
- (26) Petrichloral
- (27) Phenobarbital
- (28) Prazepam
- (29) Quazepam
- (30) Suvorexant
- (31) Temazepam
- (32) Triazolam
- (33) Zopiclone

B.D. FENFLURAMINE: Any material, compound, mixture or preparation which contains any quantity of the following substance, including its salts, isomers (whether ~~optical position~~ optical, positional or geometric) and its salts, or such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: Fenfluramine

C.E. LORCASERIN: Any material, compound, mixture or preparation which contains any quantity of the following substance, including its salts, isomers (whether ~~optical position,~~ optical, positional or geometric) and its salts, or such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: Lorcaserin

E.F. OTHER SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:

- (1) Dextropropoxyphene(Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionybutane)
- (2) Pentazocine
- (3) Carisoprodol
- (4) Nalbuphine Hydrochloride
- (5) Butorphanol Tartrate
- (6) Dezocine
- (7) Dichloralphenazone
- (8) Zaleplon
- (9) Zolpidem
- (10) Tramadol
- (11) Eluxadolone (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers.

G. EXEMPTION OF CHLORAL: When packaged in a sealed, oxygen-free environment, under nitrogen pressure, safeguarded against exposure to the air. Chloral when existing under the above conditions is a substance which is not intended for general administration to a human being or another animal, and contains no narcotic

controlled substances and is packaged in such a form that the package quantity does not present any significant potential for abuse. All persons who engage in industrial activities with respect to such chloral are subject to registration; but shall be exempt from Section 30-31-16 through 19 of the New Mexico Controlled Substances Act and 16.19.20.19 NMAC through 16.19.20.52 NMAC of the board of pharmacy regulations.

H. EXEMPT COMPOUNDS: Librax and Menrium are preparations which contain chlordiazepoxide, a depressant listed in Schedule IV, 16.19.20.68.A.5 NMAC and other ingredients in such combinations, quantity, preparation or concentration as to vitiate the potential for abuse of chlordiazepoxide, and are hereby exempt preparations.

- (1) Librax
- (2) Menrium, 5-2
- (3) Menrium, 4-5
- (4) Menrium, 10-4

[16.19.20.68 NMAC - Rp 16 NMAC 19.20.28(3), 07-15-02; A, 06-30-05; A, 05-14-10; A, 03-07-11; A, 08-31-12; A, 09-07-14; A, 12-13-15; A, 03-29-17]